

January 29, 2021

Josep Bassaganya-Riera
Chairman, President and Chief Executive Officer
Landos Biopharma, Inc.
1800 Kraft Drive, Suite 216
Blacksburg, VA 24060

Inc.

Registration Statement on Form S-1
2021

Re: Landos Biopharma,
Amendment No. 1 to
Filed January 28,
File No. 333-252083

Dear Dr. Bassaganya-Riera:

We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1

Prospectus Summary
Overview, page 1

1. We note your response to prior comment 1 and your updated disclosure which states, in part, that your clinical trial was conducted to "demonstrate" the safety and efficacy of BT-11. Safety and efficacy are determinations that are solely within the purview of the FDA and foreign regulators. Please revise your statement here and in Business to remove any implication that the Phase 2 trial of BT-11 demonstrated safety and efficacy.

We further note your statement that the Phase 2 trial was not conducted to establish statistical significance, but rather to inform the design of the Phase 3 trial. Your disclosure

on page 111 indicates that goal of the Phase 2 trial was to establish the safety and efficacy

Josep Bassaganya-Riera
Landos Biopharma, Inc.
January 29, 2021
Page 2

of BT-11. Please reconcile your disclosure here and in Business. Alternatively, please

remove this portion of the newly-added disclosure. Condensed consolidated statement of operations and comprehensive loss, page F-25

2. Please revise the earnings per share calculation presented here to reflect the 1.8249-for-1 stock split consistent with the disclosure on page F-37. In this regard, ensure that the stock split has been retroactively applied throughout the document in every instance in

consideration of SAB Topic 4C.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

You may contact Jenn Do at 202-551-3743 or Kevin Kuhar at 202-551-3662 if you have questions regarding comments on the financial statements and related matters. Please contact Alan Campbell at 202-551-4224 or Chris Edwards at 202-551-6761 with any other questions.

FirstName LastNameJosep Bassaganya-Riera

Corporation Finance
Comapany NameLandos Biopharma, Inc.

Sciences
January 29, 2021 Page 2
cc: Eric Blanchard
FirstName LastName

Sincerely,

Division of

Office of Life